About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01

THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01

THX Pharma (Theranexus) and Exeltis have reached a pivotal milestone, setting the stage for the regulatory submission of TX01 for Gaucher and Niemann-Pick type C diseases

Lyon, France – Madrid, Spain – October 14, 2025 – 6.30pm CEST – THX Pharma (Theranexus), a pharmaceutical company specializing in treatments for rare neurological diseases, and Exeltis, a global pharmaceutical company within the Insud Pharma group, announce the successful completion of the first major milestone in their license and supply agreement for TX01. This achievement marks a significant step towards bringing TX01 to patients with Gaucher and Niemann-Pick type C diseases.

With this milestone, both companies are on track to submit Marketing Authorization Applications for TX01 as planned, paving the way for commercialization in 2027 in Europe, followed by launches in Latin America and certain Middle Eastern countries.

In addition to the upfront payment received at the signature of the agreement – regarding which Exeltis will not exercise its right to reimbursement, foreseen in the agreement in the event of THX Pharma's failure to provide the required documentation before October 31, 2025 – THX Pharma is eligible for further regulatory and commercial milestone payments and royalties based on the product's net sales.

TX01 is a novel formulation of an already approved compound indicated in the treatment of rare neurological diseases such as Gaucher and Niemann-Pick type C. This partnership confirms the commitment of both companies to delivering new therapies and addressing significant unmet medical needs.

Mathieu Charvériat, CEO of THX Pharma, commented: "The timely completion of this milestone demonstrates our commitment to advancing TX01's regulatory journey. This step brings us closer to the global commercialization of TX01, delivering a transformative therapy for patients with Niemann-Pick type C and Gaucher diseases."

Salustiano Perez, General Manager of Exeltis, added: "We are pleased to reach this milestone with THX Pharma, the result of a fruitful collaboration. We can now confidently proceed with the plan to apply for TX01's registration in the first quarter of 2026 and, commercialization in Europe expected as early as 2027."

About THX Pharma

THX Pharma (Theranexus) is a pharmaceutical company specializing in treatments for rare neurological diseases. Its first drug, TX01, is expected to be commercialized soon—particularly in Europe by Exeltis, but also in the United States, Canada, and Australia—for Niemann-Pick type C disease and Gaucher disease. Its second drug, Batten-1, targets the juvenile form of Batten disease and could become the first approved therapy for this condition. THX Pharma also has an innovative antisense oligonucleotide platform, codeveloped with leading research laboratories, dedicated to rare neurological diseases. THX Pharma, a trade name of Theranexus, is listed on Euronext Growth Paris (FR0013286259 – ALTHX).


About the Insud Pharma Group

Insud Pharma is a pharmaceutical group with a history spanning over 45 years, present in around 50 countries, with 9,000 employees worldwide and 20 production sites. Insud Pharma operates across the entire pharmaceutical industry value chain, offering its expertise in scientific research, development, production, sales, registration and marketing of a wide range of active pharmaceutical ingredients (APIs), finished dosage forms (FDFs), and branded and innovative medicines for human and veterinary care, as well as biopharmaceutical products. Insud Pharma is committed to improving global health by providing accessible, effective, safe, and high-quality treatments through its various business units, with continuous investment in R&D and the latest technologies. Through its brand Exeltis, Insud Pharma holds a leading position in women's health and is a key player in Central Nervous System therapies.

For more information: http://www.thxpharma.com

Click and follow us on LinkedIn

Contacts :

THX PHARMA
Christine PLACET

Chief Financial Officer
contact@thxpharma.com

FP2COM
Florence PORTEJOIE
Media Relations

+ 33 (0)6 07 76 82 83
fportejoie@fp2com.fr

Disclaimer

This press release contains forward-looking statements relating to THX Pharma (Theranexus) and its activities, including its prospects and product development. Theranexus believes that these forward-looking statements are based on reasonable assumptions. However, forward-looking statements are not guarantees of future performance, as they relate to future events and depend on circumstances that may or may not occur in the future, and on various risks and uncertainties, including those described in the universal registration document filed by the company with the AMF (Autorité des Marchés Financiers) on April 29, 2025, under number D.25-0350, a copy of which is available on the company's website (www.theranexus.com), and on changes in the economic situation.



This publication embed "🔒 Actusnews SECURITY MASTER".
- SECURITY MASTER Key: l2qdlshmk2uclnJrZpdtm5KUb2uWm2DGZ5XIxWlpmJubmZ9lyWdqaJXGZnJlmm5q
- Check this key: https://www.security-master-key.com.



Regulated information:
Inside Information:
- other releases


Full and original press release in PDF: https://www.actusnews.com/news/94594-thx_pharma_exeltis_pr_commercialization_tx01_vdef.pdf

Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.